Pharmaceutical-grade ferric organic compounds, uses thereof and methods of making same

Inactive Publication Date: 2019-09-05
PANION & BF BIOTECH INC
View PDF16 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0073]The compositions encompassing pharmaceutical grade ferric citrate may be administered for varying periods of time. In some embodiments, the tolerability of the compositions encompassing pharmaceutical grade ferric citrate allows for long term administration when necessary.

Problems solved by technology

However, commercially scalable manufacturing processes with quality control / analysis measures to ensure and / or to verify the compliance of the pharmaceutical-grade ferric citrate or ferric organic compounds with established standards or specifications were not previously disclosed.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical-grade ferric organic compounds, uses thereof and methods of making same
  • Pharmaceutical-grade ferric organic compounds, uses thereof and methods of making same
  • Pharmaceutical-grade ferric organic compounds, uses thereof and methods of making same

Examples

Experimental program
Comparison scheme
Effect test

example 1

ethod for Synthesis of a Pharmaceutical-Grade Ferric Citrate

[0132]Referring to FIG. 1, which shows a general method of synthesis of the pharmaceutical-grade ferric citrate according to the invention, the flow chart shows implementation of quality control measures at selected stages of the synthesis process to ensure the final ferric citrate product complies with the Manufacture Release Specification as shown in Table A or any established Manufacture Release Specification for pharmaceutical-grade ferric citrate which have been approved or are suitable for human use. Other quality control measures or procedures, which are readily apparent to one of ordinary skill in the art, can be used or incorporated into the pharmaceutical-grade synthesis process to maintain the quality and purity of the final product and to increase the efficiency and yield of the synthesis process. See, for example, QC10 and QC11 in FIG. 1.

[0133]Examples of quality control measures employed in the synthesis proce...

example 1a

thod for Synthesis of a Pharmaceutical-Grade Ferric Organic Compounds

[0135]Referring to FIG. 10, which shows a general method of synthesis of the pharmaceutical-grade ferric organic compounds according to the invention, the flow chart shows implementation of quality control measures at selected stages of the synthesis process to ensure the final ferric citrate product complies with established Manufacture Release Specification for pharmaceutical-grade ferric organic compounds which have been approved or are suitable for human use. Other quality control measures or procedures, which are readily apparent to one of ordinary skill in the art, can be used or incorporated into the pharmaceutical-grade synthesis process to maintain the quality and purity of the final product and to increase the efficiency and yield of the synthesis process. See, for example, QC10A and QC11A in FIG. 10.

[0136]Examples of quality control measures employed in the synthesis process include: (QC4A) maintaining p...

example 2

y Profile of Ferric Organic Compounds According to the Invention

[0138]The ferric organic compounds produced according to the methods described above are more soluble than commercially available ferric organic compounds, over a wider range of pH levels. This increase in solubility of the ferric organic compounds of the present invention is believed to be a result of the unique significantly large active surface area of the ferric organic compounds of the present invention. For example, at pH 8.0, the intrinsic dissolution rate of ferric citrate of the present invention is 3.08 times greater than the commercially available ferric citrate. See Table 1.

[0139]The intrinsic dissolution rates of commercially available ferric citrate were compared with the ferric citrate of the present invention. The intrinsic dissolution rate is defined as the dissolution rate of pure substances under the condition of constant surface area. The dissolution rate and bioavailability of a drug substance is in...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
temperatureaaaaaaaaaa
pHaaaaaaaaaa
temperatureaaaaaaaaaa
Login to view more

Abstract

The present invention discloses pharmaceutical-grade ferric organic compounds, including ferric citrate, which are soluble over a wider range of pH, and which have a large active surface area. A manufacturing and quality control process for making a pharmaceutical-grade ferric citrate that consistently complies with the established Manufacture Release Specification is also disclosed. The pharmaceutical-grade ferric organic compounds are suitable for treating disorders characterized by elevated serum phosphate levels.

Description

[0001]This application is a Continuation of U.S. Ser. No. 14 / 306,756, filed Jun. 17, 2014, which is a Continuation of U.S. Ser. No. 13 / 661,558, filed Oct. 26, 2012, which is a Continuation of U.S. Ser. No. 13 / 289,048, filed Nov. 4, 2011, which is a Continuation of U.S. Ser. No. 12 / 064,058, filed Feb. 18, 2008, which is a National Stage of International Application No. PCT / US2006 / 032385, filed Aug. 18, 2006, which claims the benefit of U.S. Ser. No. 60 / 709,511, filed Aug. 19, 2005, and is a Continuation-in-part of U.S. Ser. No. 11 / 206,981, filed Aug. 18, 2005, which is a Continuation-in-part of Int'l App'l No. PCT / US2004 / 004646, filed Feb. 18, 2004, which claims the benefit of U.S. Ser. No. 60 / 462,684, filed Apr. 15, 2003, and U.S. Ser. No. 60 / 447,690, filed Feb. 19, 2003. The entire contents and disclosures of the preceding applications are incorporated herein by reference into this application.[0002]Throughout this application, various publications are referenced. Disclosures of th...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K33/26C07C59/265A61K31/295C07C51/41C07F15/02
CPCA61K33/26C07C59/265C07C51/418C07C51/412A61K31/295A61P3/12A61P39/04C07C55/10C07C59/255C07C53/08C07C59/245C07C57/15C07F15/02A01N37/00C07F15/025C07C51/41
Inventor CHAN, KEITHTOWN, WINSTONKWOK, DAVID W.K.STOYNOV, NIKOLAY MINTCHEV
Owner PANION & BF BIOTECH INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap